In this context, in a small cross-sectional study of 230 individuals who underwent Fibroscan®, Patel et al. showed that patients with NAFLD were more likely to have HbA1c levels ≥7% (≥53 mmol/mol) and to be treated with insulin [13]. This evidence concerns the gene INS and metabolic dysfunction-associated steatotic liver disease.